Inhibition of cytochrome P450 3A by clarithromycin uniformly affects the pharmacokinetics and pharmacodynamics of oxycodone in young and elderly volunteers

Journal of Clinical Psychopharmacology

Volumn 31, Issue 3, 2011, Pages 302-308

  Liukas, Antti ^a   Hagelberg, Nora M ^a   Kuusniemi, Kristiina ^a   Neuvonen, Pertti J ^b   Olkkola, Klaus T ^a  

^a TURKU UNIVERSITY HOSPITAL   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

Author keywords

clarithromycin; CYP3A4; interaction; oxycodone

Indexed keywords

CLARITHROMYCIN; NALOXONE; NOROXYCODONE; OXYCODONE; OXYMORPHONE; PLACEBO; UNCLASSIFIED DRUG;

ADULT; AGED; ANALGESIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG CLEARANCE; DRUG EFFECT; DRUG ELIMINATION; DRUG HALF LIFE; ENZYME INHIBITION; FEMALE; GROUPS BY AGE; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; PHARMACODYNAMICS; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADULT; AGE FACTORS; AGED; ANALGESICS, OPIOID; ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; CLARITHROMYCIN; CROSS-OVER STUDIES; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 CYP3A; DRUG INTERACTIONS; EYE MOVEMENTS; FEMALE; GENOTYPE; HALF-LIFE; HUMANS; MALE; OXYCODONE; PAIN THRESHOLD; PUPIL;

EID: 79955608886     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0b013e3182189892     Document Type: Article

References (47)

1. Garcia del Pozo J, Carvajal A, Viloria JM, et al. Trends in the consumption of opioid analgesics in Spain. Higher increases as fentanyl replaces morphine. Eur J Clin Pharmacol. 2008;64:411-415.
2. Hamunen K, Paakkari P, Kalso E. Trends in opioid consumption in the Nordic countries 2002-2006. Eur J Pain. 2009;13:954-962.
3. Sullivan M, Edlund MJ, Fan MY, et al. Trends in use of opioids for non-cancer pain conditions 2000-2005 in commercial and Medicaid insurance plans: the TROUP study. Pain. 2008;138:440-449.
4. Boudreau D, Von Korff M, Rutter CM, et al. Trends in long-term opioid therapy for chronic non-cancer pain. Pharmacoepidemiol Drug Saf. 2009;18:1166-1175.
5. Fredheim OMS, Skurtveit S, Breivik H, et al. Increasing use of opioids from 2004 to 2007Vpharmacoepidemiological data from a complete national prescription database in Norway. Eur J Pain. 2010;14:289-294.
6. Bell JS, Klaukka T, Ahonen J, et al. National utilization of transdermal fentanyl among community-dwelling older people in Finland. Am J Geriatr Pharmacother. 2009;7:355-361.
7. Pöyhiä R, Seppälä T, Olkkola KT, et al. The pharmacokinetics and metabolism of oxycodone after intramuscular and oral administration to healthy subjects. Br J Clin Pharmacol. 1992;33:617-621.
8. Nieminen TH, Hagelberg NM, Saari TI, et al. Rifampin greatly reduces the plasma concentrations of intravenous and oral oxycodone. Anesthesiology. 2009;110:1371-1378.
9. Saari TI, Grönlund J, Hagelberg NM, et al. Effects of itraconazole on the pharmacokinetics and pharmacodynamics of intravenously and orally administered oxycodone. Eur J Clin Pharmacol. 2010;66:387-397.
10. Lalovic B, Phillips B, Risler LL, et al. Quantitative contribution of CYP2D6 and CYP3A to oxycodone metabolism in human liver and intestinal microsomes. Drug Metab Dispos. 2004;32:447-454. (Pubitemid 38420280)
11. Lalovic B, Kharasch E, Hoffer C, et al. Pharmacokinetics and pharmacodynamics of oral oxycodone in healthy human subjects: role of circulating active metabolites. Clin Pharmacol Ther. 2006;79:461-479.
12. Kirvelä M, Lindgren L, Seppälä T, et al. The pharmacokinetics of oxycodone in uremic patients undergoing renal transplantation. J Clin Anesth. 1996;8:13-18. (Pubitemid 26068222)
13. Schwartz JB. The current state of knowledge on age, sex, and their interactions on clinical pharmacology. Clin Pharmacol Ther. 2007;82:87-96. (Pubitemid 46944201)
14. Hagelberg NM, Nieminen TH, Saari TI, et al. Voriconazole drastically increases exposure to oral oxycodone. Eur J Clin Pharmacol. 2009;65:263-271.
15. Nieminen TH, Hagelberg NM, Saari TI, et al. Grapefruit juice enhances the exposure to oral oxycodone. Basic Clin Pharmacol Toxicol. 2010;107(4):782-788. Doi: 10.1111/j.1742-7843.2010.00582.x.
16. Cotreau M, von Moltke L, Greenblatt D. The influence of age and sex on the clearance of cytochrome P450 3A substrates. Clin Pharmacokin. 2005;44(1):33-60. (Pubitemid 40100551)
17. Greenblatt D, Harmatz J, von Moltke L, et al. Age and gender effects on the pharmacokinetics and pharmacodynamics of triazolam, a cytochrome P450 3A substrate. Clin Pharmacol Ther. 2004;76:467-479. (Pubitemid 39469870)
18. Nieminen TH, Hagelberg NM, Saari TI, et al. St John's wort greatly reduces the concentrations of oral oxycodone. Eur J Pain. 2010;14(8):854-859. [Epub 2010 Jan 27]. Doi: 10.1016/j.ejpain. 2009.12.007.
19. Gorski JC, Jones DR, Haehner-Daniels BD, et al. The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin. Clin Pharmacol Ther. 1998;64:133-143. (Pubitemid 28423848)
20. Rodrigues AD, Roberts EM, Mulford DJ, et al. Oxidative metabolism of clarithromycin in the presence of human liver microsomes. Major role for the cytochrome P450A (CYP3A) subfamily. Drug Metab Disp. 1997;25:623-630. (Pubitemid 27213105)
21. Pinto AG, Wang Y-H, Chalasani N, et al. Inhibition of human intestinal wall metabolism by macrolide antibiotics: effect of clarithromycin on cytochrome P450 3A4/5 activity and expression. Clin Pharmacol Ther. 2005;77:178-188. (Pubitemid 40269133)
22. Greenblatt DJ, von Moltke LL, Harmatz JS, et al. Inhibition of triazolam clearance by macrolide antimicrobial agents: in vitro correlates and dynamic consequences. Clin Pharmacol Ther. 1998;64:278-285. (Pubitemid 28462288)
23. Westphal JF. Macrolide - induced clinically relevant drug interactions with cytochrome P-450A (CYP) 3A4: an update focused on clarithromycin, azithromycin and dirithromycin. Br J Clin Pharmacol. 2000;50:285-295.
24. Farkas D, Volak LP, Harmatz JS, et al. Short-term clarithromycin administration impairs clearance and enhances pharmacodynamic effects of trazodone but not of zolpidem. Clin Pharmacol Ther. 2009;85:644-650.
25. Michna E, Ross EL, Hynes WL, et al. Predicting aberrant drug behavior in patients treated for chronic pain: importance of abuse history. J Pain Symptom Manage. 2004;28:250-258. (Pubitemid 39158807)
26. Neuvonen M, Neuvonen PJ. Determination of oxycodone, noroxycodone, oxymorphone and noroxymorphone in human plasma by liquid chromatographyYelectrosprayYtandem mass spectrometry. Ther Drug Monit. 2008;30:333-340.
27. Rooyen GF, Smit MJ, de Jager AD, et al. Sensitive liquid chromatographyYtandem mass spectrometry method for the determination of clarithromycin in human plasma. J Chromatogr B. 2002;768:223-229. (Pubitemid 34158856)
28. Sistonen J. CYP2D6 genotyping by a multiplex primer extension reaction. Clin Chem. 2005;51:1291-1295. (Pubitemid 43079419)
29. Bond A, Lader M. The use of analogue visual scales in rating subjective feelings. Br J Med Psychol. 1974;47:211-218.
30. Hannington-Kiff JG. Measurements of recovery from outpatient general anaesthesia with a simple ocular test. BMJ. 1970;3:132-135.
31. Stone BM. Pencil and paper testsVsensitivity to psychotropic drugs. Br J Clin Pharmacol. 1984;18(suppl 1):15S-20S. (Pubitemid 15184100)
32. Cogan DG. Simplified entoptic pupillometer. Am J Ophthalmol. 1941;24:1431-1433.
33. Jones SF, McQuay HJ, Moore RA, et al. Morphine and ibuprofen compared using the cold pressor test. Pain. 1988;34:117-122.
34. Pöyhiä R, Olkkola KT, Seppälä T, et al. The pharmacokinetics of oxycodone after intravenous injection in adults. Br J Clin Pharmacol. 1991;32:516-518.
35. Samer CF, Daali Y, Wagner M, et al. The effects of CYP2D6 and CYP3A activities on the pharmacokinetics of immediate release oxycodone. Br J Pharmacol. 2010;160(4):907-918.
36. Eberl S, Renner B, Neubert A, et al. Role of p-glycoprotein inhibition for drug interactions. Evidence form in vitro and pharmacoepidemiological studies. Clin Pharmacokinet. 2007;46:1039-1049. (Pubitemid 350136910)
37. Ohno Y, Akihiro H, Hiroshi S. General framework for the quantitative prediction of CYP3A4-mediated oral drug interactions based on the AUC increase by coadministration of standard drugs. Clin Pharmacokinet. 2007;46:681-696. (Pubitemid 47204854)
38. Zhou SF. Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4 [review]. Curr Drug Metab. 2008;9(4):310-322.
39. Schmucker DL, Woodhouse KW, Wang RK, et al. Effects of age and gender on in vitro properties of human liver microsomal monooxygenases. Clin Pharmacol Ther. 1990;48:365-374. (Pubitemid 20362269)
40. Parkinson A, Mudra D, Johnson C, et al. The effects of gender, age, ethnicity, and liver cirrhosis on cytochrome P450 enzyme activity in human liver microsomes and inducibility in cultured human hepatocytes. Toxicol Appl Pharmacol. 2004;199:193-209. (Pubitemid 39208721)
41. Schwartz JB. Erythromycin breath test in very old and frail persons. Clin Pharmacol Ther. 2006;79:440-448.
42. Liukas A, Kuusniemi K, Aantaa R, et al. Plasma concentrations of oral oxycodone are greatly increased in the elderly. Clin Pharmacol Ther. 2008;84:462-467.
43. Kaiko RF, Benziger DP, Fitzmartin RD, et al. Pharmacokinetic- pharmacodynamic relationships of controlled-release oxycodone. Clin Pharmacol Ther. 1996;59(1):52-61. (Pubitemid 26048692)
44. Cherrier M, Amory JK, Ersek M, et al. Comparative cognitive and subjective side effects of immediate-release oxycodone in healthy middle-aged and older adults. J Pain. 2009;10:1038-1050.
45. Klotz U. Pharmacokinetics and drug metabolism in the elderly. Drug Metab Rev. 2009;41:67-76.
46. Sarton E, Olofsen E, Romberg R, et al. Sex differences in morphine analgesia: an experimental study in healthy volunteers. Anesthesiology. 2000;93:1245-1254.
47. Koltzenburg M, Pokorny R, Gasser UE, et al. Differential sensitivity of three experimental pain models in detecting the analgesic effects of transdermal fentanyl and buprenorphine. Pain. 2006;126:165-174. (Pubitemid 44802773)